<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> accounts for approximately 15-20% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0000726'>dementias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In addition, a significant subset of people with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> have concurrent cerebrovascular disease </plain></SENT>
<SENT sid="2" pm="."><plain>Vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> is caused by different cerebrovascular morphological abnormalities including large artery territory infarction (multi-<z:mpath ids='MPATH_124'>infarct</z:mpath> vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>) and sub-cortical ischaemic vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Despite this distinction, there is a lack of studies examining the neurochemistry of individual vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> subtypes </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="19" ids="28790">Serotonin</z:chebi> is believed to play an important role in cognition, and <z:chebi fb="19" ids="28790">serotonin</z:chebi> receptors may provide a novel target for future anti-<z:hpo ids='HP_0000726'>dementia</z:hpo> therapeutics </plain></SENT>
<SENT sid="5" pm="."><plain>This study aimed to determine levels of two <z:chebi fb="19" ids="28790">serotonin</z:chebi> receptors in subtypes of vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> and relate any changes to cognition </plain></SENT>
<SENT sid="6" pm="."><plain>We have determined, using saturation radioligand binding, the binding parameters (affinity and maximal binding) of ((3)H)-WAY 100635 binding to <z:chebi fb="0" ids="28790">5-HT</z:chebi>(1A) receptors and ((3)H)-<z:chebi fb="0" ids="6123">ketanserin</z:chebi> binding to <z:chebi fb="0" ids="28790">5-HT</z:chebi>(2A) receptors in post-mortem tissue from the frontal and temporal cortices of patients with either multi-<z:mpath ids='MPATH_124'>infarct</z:mpath> vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, sub-cortical ischaemic vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, mixed <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e>/vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> or <z:hpo ids='HP_0001297'>stroke</z:hpo> no <z:hpo ids='HP_0000726'>dementia</z:hpo> (SND) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="28790">5-HT</z:chebi>(1A) and <z:chebi fb="0" ids="28790">5-HT</z:chebi>(2A) receptor binding was significantly increased in the temporal cortex of patients with either multi-<z:mpath ids='MPATH_124'>infarct</z:mpath> vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> or SND, compared to age-matched controls </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="28790">5-HT</z:chebi>(1A) receptor maximal binding in the temporal cortex was also positively correlated with cognition as determined by Mini-Mental State Examination (MMSE) and Cambridge Assessment of Mental Health for the Elderly scores (CAMCOG) </plain></SENT>
<SENT sid="9" pm="."><plain>These results reveal an important distinction between the neurochemistry of multi-<z:mpath ids='MPATH_124'>infarct</z:mpath> vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>/SND and sub-cortical ischaemic vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, suggesting that pharmacological manipulation of <z:chebi fb="19" ids="28790">serotonin</z:chebi> offers the possibility to develop novel therapies for <z:hpo ids='HP_0001297'>stroke</z:hpo> and multi-<z:mpath ids='MPATH_124'>infarct</z:mpath> vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> patients </plain></SENT>
<SENT sid="10" pm="."><plain>The results also highlight the importance of the cortical <z:chebi fb="0" ids="28790">5-HT</z:chebi>(1A) receptor in mediating cognition </plain></SENT>
</text></document>